***Pharmaceutical Benefits Advisory Committee***

Email: PBAC@health.gov.au Address all mail to:

PBAC Secretariat

GPO Box 9848

Canberra ACT 2601

**DELISTING OF PHARMACEUTICAL BENEFIT ITEMS**

**EFFECTIVE 01 NOVEMBER 2024**

Following is the advice of the Pharmaceutical Benefits Advisory Committee (PBAC) concerning the delisting of items from the declaration under subsections 85(2) and 85(2A) of the *National Health Act* *1953*, with effect from the above date.

|  |  |
| --- | --- |
| **Item** | **PBAC Advice** |
| Ribavirin | The sponsor requested the delisting of Ibavyr® (ribavirin) from the Pharmaceutical Benefits Scheme (PBS).  The PBAC noted the low number of services in the last financial year. The PBAC advised the delisting of this product would not result in an unmet clinical need. |

Vanessa McMahon

PBAC Secretary

Office of Health Technology Assessment

Technology Assessment and Access Division

24 October 2024